PFKFB2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21856756	1.00	17/20
SCHEMBL21856778	1.00	17/20
SCHEMBL21856796	1.00	17/20
SCHEMBL21856810	1.00	17/20
SCHEMBL21856838	1.00	17/20
SCHEMBL21856728	0.93	17/20
SCHEMBL21856681	1.00	16/20
SCHEMBL21856704	1.00	16/20
SCHEMBL21856723	1.00	16/20
SCHEMBL21856749	1.00	16/20
SCHEMBL21856777	1.00	16/20
SCHEMBL21856800	1.00	16/20
SCHEMBL21856820	1.00	16/20
SCHEMBL21856828	1.00	16/20
SCHEMBL21856832	1.00	16/20
SCHEMBL21856933	1.00	16/20
SCHEMBL21857526	1.00	16/20
SCHEMBL28644324	0.85	16/20
SCHEMBL28636742	0.82	16/20
SCHEMBL21856730	0.80	16/20

Clinical trials — most relevant to PFKFB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Ketohexokinase Inhibition in NAFLD	PHASE2	COMPLETED
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC	PHASE2	UNKNOWN
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome	PHASE2	COMPLETED
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency	PHASE2	UNKNOWN
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients	PHASE2	UNKNOWN
Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies	PHASE1	UNKNOWN
Multi-Tracer PET Assessment of Primary Brain Tumors	PHASE1	COMPLETED
A Dose-Finding Study of AG-348 in Sickle Cell Disease	EARLY_PHASE1	COMPLETED
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Effect of Acute Fructose Load in Human	nan	COMPLETED
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours	nan	RECRUITING
Fructose and Glucose and TAS1R2 in Type 1 Diabetes	nan	COMPLETED
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology	nan	COMPLETED
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy	nan	COMPLETED
Early Versus Late FDG-PET/CT in Bladder Cancer	nan	COMPLETED
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors	nan	RECRUITING
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer	nan	UNKNOWN
Diagnostic Performance of 18F-FDG PET/CT in Detecting Distant Metastases in Breast Cancer	nan	NOT_YET_RECRUITING
Choline PET/CT vs. Dual Time Point FDG PET/CT in Prostate Cancer	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment	nan	UNKNOWN
Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma	nan	WITHDRAWN
Circadian Brown Adipose Tissue Metabolism	nan	COMPLETED
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS	nan	RECRUITING
Role and Expression of MXRA5 in Placental Connective Tissue Remodelling in Preeclampsia	nan	UNKNOWN
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PFKFB2 binder may also engage these)

Protein	Name	Similarity
P70265	—	1.000	P70265 →
Q9JJH5	—	1.000	Q9JJH5 →
P26285	—	1.000	P26285 →
Q4R8B6	—	1.000	Q4R8B6 →
P70266	—	1.000	P70266 →
Q5NVT1	—	1.000	Q5NVT1 →
Q6DTY7	—	1.000	Q6DTY7 →
P49872	—	1.000	P49872 →
PFKFB3	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3	1.000	landscape →
PFKFB4	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4	1.000	landscape →
O35552	—	1.000	O35552 →
Q28901	—	1.000	Q28901 →
P25114	—	1.000	P25114 →
P07953	—	1.000	P07953 →
PFKFB1	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1	1.000	landscape →
P32604	—	0.999	P32604 →
Q91309	—	0.997	Q91309 →
Q5R9C1	—	0.997	Q5R9C1 →
Q21122	—	0.996	Q21122 →
Q91348	—	0.995	Q91348 →
B4NBB0	—	0.991	B4NBB0 →
B0XDC4	—	0.990	B0XDC4 →
Q9URZ7	—	0.989	Q9URZ7 →
Q8VYB2	—	0.989	Q8VYB2 →
Q6DNF7	—	0.989	Q6DNF7 →
Q55EL3	—	0.988	Q55EL3 →
P92006	—	0.988	P92006 →
Q8TFH0	—	0.988	Q8TFH0 →
Q5RAZ4	—	0.988	Q5RAZ4 →
Q9NWZ5	—	0.987	Q9NWZ5 →